Femasys Inc (FEMY) - Net Assets
Based on the latest financial reports, Femasys Inc (FEMY) has net assets worth $5.87 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.72 Million) and total liabilities ($14.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Femasys Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.87 Million |
| % of Total Assets | 28.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | -77.71% |
| 10-Year Change | N/A |
| Growth Volatility | 266.77 |
Femasys Inc - Net Assets Trend (2019–2025)
This chart illustrates how Femasys Inc's net assets have evolved over time, based on quarterly financial data. Also explore Femasys Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Femasys Inc (2019–2025)
The table below shows the annual net assets of Femasys Inc from 2019 to 2025. For live valuation and market cap data, see Femasys Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.87 Million | +154.70% |
| 2024-12-31 | $2.30 Million | -87.44% |
| 2023-12-31 | $18.35 Million | +20.40% |
| 2022-12-31 | $15.24 Million | -42.11% |
| 2021-12-31 | $26.33 Million | +646.39% |
| 2020-12-31 | $3.53 Million | +107.78% |
| 2019-12-31 | $-45.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Femasys Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7753864600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $59.72K | 1.02% |
| Other Components | $151.64 Million | 2583.54% |
| Total Equity | $5.87 Million | 100.00% |
Femasys Inc Competitors by Market Cap
The table below lists competitors of Femasys Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hua Yang Bhd
KLSE:5062
|
$23.20 Million |
|
Peruvian Metals Corp
V:PER
|
$23.22 Million |
|
SIAV S.P.A.
F:F4U
|
$23.26 Million |
|
Alcom Group Bhd
KLSE:2674
|
$23.27 Million |
|
Alla Public Company Limited
BK:ALLA
|
$23.19 Million |
|
Klaria Pharma Holding AB
ST:KLAR
|
$23.19 Million |
|
Renrenle Commercial Group Co Ltd
SHE:002336
|
$23.18 Million |
|
Arctic Gold Publ AB
ST:ARCT
|
$23.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Femasys Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,304,422 to 5,869,302, a change of 3,564,880 (154.7%).
- Net loss of 18,627,887 reduced equity.
- New share issuances of 19,521,989 increased equity.
- Other comprehensive income decreased equity by 1,860,008.
- Other factors increased equity by 4,530,786.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.63 Million | -317.38% |
| Share Issuances | $19.52 Million | +332.61% |
| Other Comprehensive Income | $-1.86 Million | -31.69% |
| Other Changes | $4.53 Million | +77.19% |
| Total Change | $- | 154.70% |
Book Value vs Market Value Analysis
This analysis compares Femasys Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-3.86 | $0.38 | x |
| 2020-12-31 | $0.30 | $0.38 | x |
| 2021-12-31 | $2.23 | $0.38 | x |
| 2022-12-31 | $1.29 | $0.38 | x |
| 2023-12-31 | $1.19 | $0.38 | x |
| 2024-12-31 | $0.10 | $0.38 | x |
| 2025-12-31 | $0.15 | $0.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Femasys Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -317.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -812.27%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 3.53x
- Recent ROE (-317.38%) is below the historical average (-215.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -1213.26% | 0.07x | 0.00x | $-6.73 Million |
| 2020 | -196.01% | -666.24% | 0.14x | 2.16x | $-7.27 Million |
| 2021 | -28.63% | -638.97% | 0.04x | 1.09x | $-10.17 Million |
| 2022 | -74.75% | -944.62% | 0.07x | 1.11x | $-12.92 Million |
| 2023 | -77.63% | -1329.06% | 0.04x | 1.51x | $-16.08 Million |
| 2024 | -816.54% | -1155.03% | 0.13x | 5.40x | $-19.05 Million |
| 2025 | -317.38% | -812.27% | 0.11x | 3.53x | $-19.21 Million |
Industry Comparison
This section compares Femasys Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,863,507,886
- Average return on equity (ROE) among peers: -17.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Femasys Inc (FEMY) | $5.87 Million | 0.00% | 2.53x | $23.19 Million |
| Akoya Biosciences Inc (AKYA) | $121.35 Million | -35.38% | 0.57x | $64.44 Million |
| Align Technology Inc (ALGN) | $1.35 Billion | 32.89% | 0.86x | $12.66 Billion |
| AngioDynamics Inc (ANGO) | $517.03 Million | -1.36% | 0.37x | $444.32 Million |
| AptarGroup Inc (ATR) | $2.71 Billion | 14.48% | 0.94x | $7.66 Billion |
| AtriCure Inc (ATRC) | $16.74 Million | -22.66% | 1.01x | $1.44 Billion |
| Avinger Inc (AVGR) | $-73.64 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $10.52 Million | -163.15% | 1.04x | $156.14 Million |
| Avantor Inc (AVTR) | $5.57 Billion | -9.53% | 1.12x | $5.43 Billion |
| Azenta Inc (AZTA) | $553.69 Million | -12.55% | 0.24x | $1.04 Billion |
| Baxter International Inc (BAX) | $7.87 Billion | 19.65% | 1.00x | $8.85 Billion |
About Femasys Inc
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornua… Read more